Skip to main content
OpenTrials

Clinical trial condition

alpha 1-Antitrypsin Deficiency

Explore clinical trials studying alpha 1-Antitrypsin Deficiency. Study availability and eligibility vary by location and protocol.

100 public trials 19 recruiting studies
Refine in advanced search Browse all conditions

alpha 1-Antitrypsin Deficiency trial results

Completed

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

NCT04474197

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • University of California Davis Medical Center Sacramento, California, United States
  • National Jewish Health Denver, Colorado, United States
View all 30 locations
View Trial Details
Completed

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

NCT03636347

Conditions
Alpha 1-Antitrypsin Deficiency, COPD, Chronic Disease, +14 more
Locations
  • University of Alabama, Birmingham (UAB) Birmingham, Alabama, United States
  • UCLA Medical Center Los Angeles, California, United States
  • UC Davis Medical Centre Sacramento, California, United States
  • PMG Research of Wilmington Wilmington, North Carolina, United States
View all 26 locations
View Trial Details
Completed

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

NCT02525861

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • Arizona Board of Regents, University of Arizona Tucson, Arizona, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Cedars Sinai Medical Center, Division of Pulmonary and Critical Care Medicine Los Angeles, California, United States
  • University of California Davis Health System Sacramento, California, United States
View all 18 locations
View Trial Details
Completed

GLASSIA Infusion Rate Study

NCT01651351

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +11 more
Locations
  • Overland Park, Kansas, United States
View Trial Details
Completed

Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

NCT00242385

Conditions
Alpha 1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • Adelaide, South Australia, Australia
  • Woodville, South Australia, Australia
  • Fitzroy, Victoria, Australia
  • Nedlands, Western Australia, Australia
View Trial Details
Completed

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

NCT00396006

Conditions
Alpha 1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • Adelaide, South Australia, Australia
  • Melbourne, Victoria, Australia
  • Nedlands, Western Australia, Australia
  • Otahuhu, Auckland, New Zealand
View Trial Details
Completed

Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

NCT00161707

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • National Jewish Medical and Research Center Denver, Colorado, United States
  • Shands Hospital at the University of Florida Gainesville, Florida, United States
  • Cleveland Clinic Foundation, Department of Pulmonary and Critical Care Medicine Cleveland, Ohio, United States
  • The University of Texas Health Science Center at Tyler Tyler, Texas, United States
View Trial Details

Related conditions